Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Oppenheimer initiated coverage on Gossamer Bio Inc (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.
Oppenheimer對Gossamer Bio Inc (納斯達克:GOSS)進行了覆蓋，評定爲Outperform，並給出了9美元的價格目標。請使用moomoo賬號登錄以查看。
Gossamer Bio is focused on developing and commercializing seralutinib for pulmonary arterial hypertension. It stands out with its clean long-term safety profile, Oppenheimer said.
Gossamer Bio專注於開發和推廣治療肺動脈高壓的seralutinib。Oppenheimer表示，該公司的長期安全性良好，具有優點。
Competitors like Merck & Co Inc's (NYSE:MRK) Winrevair require frequent monitoring for hemoglobin increases, thrombocytopenia, and gastrointestinal bleeding. It may require dose reductions or drug holidays.
像Merck & Co Inc (紐交所:MRK)的Winrevair這樣的競爭對手需要經常檢測血紅蛋白增加，血小板減少和胃腸道出血。它可能需要減少藥量或停藥。
In May, Gossamer Bio and Italy-based Chiesi Farmaceutici S.p.A entered a global collaboration and license agreement to develop and commercialize seralutinib.
今年5月，Gossamer Bio與總部位於意大利的Chiesi Farmaceutici SpA簽署了全球合作和許可協議，以開發和推廣Seralutinib。
Following the readout of the Phase 2 TORREY Study in patients with PAH, Gossamer initiated the Phase 3 PROSERA Study in 2023.
在PAH（肺動脈高壓）患者的TORREY II期研究結果公佈後，Gossamer Bio在2023年啓動了III期PROSERA研究。
Gossamer and Chiesi plan to initiate a global Phase 3 registrational study in pulmonary hypertension associated with interstitial lung disease (PH-ILD) in mid-2025 and to evaluate seralutinib in additional indications.
Gossamer與Chiesi計劃在2025年中期開始全球III期註冊研究，探索與interstitial lung disease（PH-ILD）相關的肺高壓（PH）其他應用前景。
Oppenheimer says including Japanese trial sites could help seralutinib gain approval in Japan, the world's second-largest PAH market, and attract potential partnerships. Additionally, delays for WInrevair in Europe underscore the importance of opportunities outside the U.S.
Oppenheimer表示，包括日本在內的試驗站點可能有助於Seralutinib在世界第二大PAH市場日本獲得批准，並吸引潛在合作伙伴。此外，WInrevair在歐洲的延遲突顯出海外機會的重要性。
Seralutinib's safety and efficacy profile are "a preferred choice among severe PAH patients who are not adequately served by currently available therapies (~65% take 2-3 drugs)," analysts noted.
分析師指出，Seralutinib的安全性和療效“成爲嚴重PAH患者（約65%患者攝入2-3種藥物）的首選”。
The analyst adds that Gossamer has strategically positioned seralutinib to enter large, underserved markets such as Japan. "We see shares trading below cash as creating an attractive entry point at current levels."
分析師補充說，Gossamer已經將Seralutinib戰略定位爲進入包括日本在內的一些大型、未得到服務的市場。 “我們認爲股價低於現金水平，在當前水平上進入非常具有吸引力。”
With pro forma cash of $396 million providing sufficient runway into the second quarter of 2026 and shares currently trading below cash, this can be seen as an attractive entry for long-term investors.
目前股票交易價格低於現金水平，加上募資後現金達3.96億美元，足夠支撐到2026年第二季度，這對於長期投資者是一個有吸引力的入場機會。
Price Action: GOSS shares are up 21.1% at $1.00 at last check Tuesday.
GOSS股票價格在週二最後一次檢查時上漲21.1%，爲1.00美元。
Now Read: Chipmakers, Cruise Lines, Crypto Rally, Nvidia Reclaims $3 Trillion; Blue Chips, Small Caps Dip: What's Driving Markets Tuesday?
芯片製造商、郵輪概念、加密貨幣上漲，英偉達收復3萬億美元；藍籌股、小市值股票下跌：週二市場動態。
譯文內容由第三人軟體翻譯。